The Medicines Control Authority of Zimbabwe (MCAZ) has issued an urgent national health alert following the discovery of falsified Cloxacillin 250mg capsules that are circulating within the market under the guise of being produced by Varichem Pharmaceuticals (Pvt) Ltd. This alert, contained in Circular No. 21 of 2025 dated 25 July 2025, underscores a growing concern over unregulated medicine distribution channels and the public health threat posed by counterfeit antibiotics.
According to MCAZ Director-General Mr. R. Rukwata, the falsified Cloxacillin has been distributed through unauthorised suppliers, with Gartas Investments singled out as one of the identified sources. The fake medicine is not only an illegal imitation but also a direct danger to patients due to potential treatment failure, harmful ingredients, and the serious risk of promoting antimicrobial resistance (AMR)—a growing global health crisis that threatens to undermine decades of medical progress.
MCAZ has instructed all licensed pharmacies, hospitals, clinics, and wholesalers to immediately quarantine any units of the falsified product and submit them for safe disposal by 1 August 2025. In a further effort to protect consumers, members of the public are being urged to return the counterfeit medicine to the pharmacy from which it was purchased.
This alert once again throws into sharp focus the importance of sourcing medicines strictly from authorised and regulated channels. Counterfeit medicines not only compromise the recovery of patients but also erode public trust in healthcare institutions and supply systems. The spread of fake pharmaceuticals, especially antibiotics, creates long-term national health challenges by encouraging the emergence of drug-resistant bacteria—making common infections harder and more expensive to treat.
The MCAZ’s proactive stance in identifying and issuing a public notice on the fake Cloxacillin is commendable and represents the vigilant role regulatory authorities must play in upholding patient safety. Pictures to assist healthcare providers and consumers in detecting the falsified medicine have been attached to the circular to aid in quick identification and response.
In light of this, there is a growing call for strengthened law enforcement collaboration with regulatory bodies like MCAZ to clamp down on rogue distributors and protect Zimbabwe’s health system from further contamination. This incident also invites renewed investment in public awareness campaigns around medicine safety, ensuring that Zimbabweans remain alert, informed, and safe in a market increasingly challenged by illicit pharmaceuticals.
As the country moves towards Vision 2030 and aims to strengthen its healthcare delivery, stopping the infiltration of falsified medicines must remain a top priority. MCAZ’s swift action should serve as a strong deterrent to all would-be counterfeiters and a wake-up call to healthcare providers to tighten procurement protocols and regulatory compliance.
